There are currently 148 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. The states with the highest number of trials for Non-Small Cell Lung Cancer participants are California, Texas, Florida and New York.
Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
NCT04878952
Recruiting
This trial will examine if the monitoring of daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce the rate of adverse events during the course of radiation treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: WellSpan Health - Chambersburg, Chambersburg, Pennsylvania +4 locations
Conditions: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Recurrent Non Small Cell Lung Cancer
Register for Updates
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer
NCT01817192
Recruiting
The optimal treatment for Stage I or Stage IIA non-small cell lung cancer (NSCLC) remains controversial. Radiographic surveillance alone has been recommended for stage I and stage IIA patients after the tumor is removed surgically from the lung, and this standard has been based on the fact that no previous clinical trial has demonstrated a benefit for Stage I or Stage IIA NSCLC patients who receive post-operative chemotherapy. These patients, however, have a substantial risk of death within five... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Highlands Oncology Group, Springdale, Arkansas +50 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care
NCT05254795
Recruiting
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
12/07/2023
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of TAS3351 in NSCLC Patients With EGFRmt
NCT05765734
Recruiting
This is a first-in-human, open label, Phase 1/2 study to investigate the safety and efficacy of TAS3351 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/20/2023
Locations: Georgetown University - Lombardi Comprehensive Cancer Center, Washington, District of Columbia +16 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384
Recruiting
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: Orchard Healthcare Research Inc., Skokie, Illinois
Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Register for Updates
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
NCT06103682
Recruiting
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/27/2023
Locations: University of California, Davis, Sacramento, California
Conditions: Non-small Cell Lung Cancer, Oligoprogressive, Small-cell Lung Cancer
Register for Updates
Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
NCT04495894
Recruiting
This is a pilot study of biomarker evaluation and safety of pre-incisional ketorolac for patients undergoing surgical resection for non-small cell lung cancer and renal cell carcinoma. There is significant promise in the use of preoperative ketorolac to decrease the inflammatory response after surgical resection of tumors, thereby potentially reducing the risk of distant metastatic tumor spread and improving survival. A total of 56 patients (28 per disease site) will be enrolled into the experim... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
10/23/2023
Locations: Emory University Hospital Midtown, Atlanta, Georgia +3 locations
Conditions: Non-small Cell Lung Cancer, Renal Cell Carcinoma
Register for Updates
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
NCT04892472
Recruiting
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to t... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
10/04/2023
Locations: Central Alabama Research, Birmingham, Alabama +23 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT02838836
Recruiting
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/28/2023
Locations: Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri
Conditions: Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Register for Updates
Biomarkers for Risk Stratification in Lung Cancer
NCT03774758
Recruiting
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.
Gender:
All
Ages:
40 years and above
Trial Updated:
09/18/2023
Locations: Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California +2 locations
Conditions: Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Register for Updates
Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
NCT05424029
Recruiting
The purpose of this study is to find out if fluid rinsed from peoples' airways (bronchial washing samples) during routine surgery to remove (resect) their non-small cell lung cancer (NSCLC) tumors contains enough vesicles to do testing that may help the researchers learn more about their NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/01/2023
Locations: Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey +6 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
NCT04795713
Recruiting
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1
Gender:
All
Ages:
18 years and above
Trial Updated:
08/17/2023
Locations: City of Hope Medical Center, Duarte, California +15 locations
Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Register for Updates